Objectives: Short-term supervised exercise reverses the loss of muscle strength and physical function in prostate cancer survivors on androgen deprivation therapy (ADT). However, limited information exists on long-term adaptations and the prescription of different exercise modalities. We examined the role of contrasting 12-month exercise programmes in ameliorating these treatment-related effects on muscle strength and physical function. Methods: 163 men (43-90 years) undertaking ADT for prostate cancer were randomized to: impact loading/resistance exercise (IMRT, n = 58) for 12-months supervised training; aerobic/resistance exercise (ART, n = 54) for 6-months supervised and 6-months home-based training; or delayed exercise (DEL, n = 51) 6-months usual care followed by 6-months supervised cycling exercise. Muscle strength (1RM; chest press, seated row, leg press, and leg extension) and physical function (6 m usual/fast/backward walks, chair rise, stair climb, 400 m walk, balance) were assessed at baseline, 6, and 12 months. Results: All strength tests had a significant interaction (p < 0.001) with strength generally increasing progressively in IMRT from baseline to 6 and 12 months, from baseline to 6-months in ART, and lower body strength from 6 to 12 months in DEL. There was also a significant interaction for repeated chair rise (p = 0.049) and a significant time effect (p < 0.001) for 400 m and all 6 m walk tests with physical function generally improving in IMRT and ART over 6 and 12 months and by 12 months in DEL. Conclusions: Different exercise modes enhance muscle strength and physical function in ADT-treated men but with highly specific adaptations. Exercise prescription should be tailored to ameliorate specific treatment related adverse effects. Objectives: Metformin is a medication that may be used to counter adverse effects of ADT such as hyperinsulinaemia. Metformin has also been shown to be a potential therapeutic agent for prostate cancer. In vitro, metformin inhibits mitochondria in prostate cancer cell lines leading to apoptosis. We explored the effects of metformin in cells treated under conditions that mimic ADT such as hyperinsulinaemia. 
Objectives: Short-term supervised exercise reverses the loss of muscle strength and physical function in prostate cancer survivors on androgen deprivation therapy (ADT). However, limited information exists on long-term adaptations and the prescription of different exercise modalities. We examined the role of contrasting 12-month exercise programmes in ameliorating these treatment-related effects on muscle strength and physical function. Methods: 163 men (43-90 years) undertaking ADT for prostate cancer were randomized to: impact loading/resistance exercise (IMRT, n = 58) for 12-months supervised training; aerobic/resistance exercise (ART, n = 54) for 6-months supervised and 6-months home-based training; or delayed exercise (DEL, n = 51) 6-months usual care followed by 6-months supervised cycling exercise. Muscle strength (1RM; chest press, seated row, leg press, and leg extension) and physical function (6 m usual/fast/backward walks, chair rise, stair climb, 400 m walk, balance) were assessed at baseline, 6, and 12 months. Results: All strength tests had a significant interaction (p < 0.001) with strength generally increasing progressively in IMRT from baseline to 6 and 12 months, from baseline to 6-months in ART, and lower body strength from 6 to 12 months in DEL. There was also a significant interaction for repeated chair rise (p = 0.049) and a significant time effect (p < 0.001) for 400 m and all 6 m walk tests with physical function generally improving in IMRT and ART over 6 and 12 months and by 12 months in DEL. Conclusions: Different exercise modes enhance muscle strength and physical function in ADT-treated men but with highly specific adaptations. Exercise prescription should be tailored to ameliorate specific treatment related adverse effects. Objective: Full-length androgen receptor (FL-AR) and AR splicing variants (ARVs) play an important role in prostate cancer progression. AR activity is regulated by phosphorylation via various protein kinases but the molecular mechanism is unclear. The objective of this study is to determine the phosphorylation changes during prostate cancer progression and relationship of the AR functions. Methods: LNCaP, 22RV1 and VCaP prostate cancer cells were used. AR transcriptional activity was measured using luciferase assay and cell proliferation was determined by BrdU incorporation and fluorescence-activated cell sorting (FACS) analysis. Information of cellular localization was obtained using immunofluorescence and subcellular fractionation methods. Expression of phosphorylation changes was determined by western blotting (in-vitro) and immunohistochemistry (in-vivo) in cancer cell line and castration resistant prostate cancer (CRPC) mouse xenograft model, respectively. Results: Phosphorylation of both FL-AR and AR-Vs was observed in various prostate cancer cells. Increased phosphorylation of the FL-AR and AR-Vs in the N-terminal domain (NTD) was observed by androgen and/or PKA signalling and validated in CRPC mouse xenograft model. Phosphorylated ARs were mainly in nucleus. Inhibition of phosphorylation of the ARs by kinase inhibitor reduced AR transcriptional activity and cell growth. We also confirmed combination of kinase inhibitor and AR NTD targeting antagonist is more effective for inhibition of cell growth. Conclusions: Our novel findings suggest that phosphorylation of ARs is important in cancer progression and provides an important role of various kinases that regulate AR and modulate cell growth, which could be an effective therapeutic approach for CRPC treatment. patients who were selected for whole genome sequencing, MSH2 was found to be lost in one patient due to a gene fusion event. A cohort of 98 recurrent and 90 nonrecurrent prostate cancer patients were investigated by immunohistochemistry to identify if MSH2 loss was consistent in a subpopulation of prostate cancers. Four recurrent patients were found to have no staining whereas all non-recurrent patients showed staining. Additionally, 24 recurrent patients and 9 non-recurrent patients were observed to have weak MSH2 staining. A break-apart fluorescence in situ hybridisation (FISH) assay was then applied to identify MSH2 translocations in all low/negative MSH2 patient samples, identifying 7 patients with translocations in the MSH2 gene. We also used this FISH assay to investigate the effect of androgens on the frequency of breaks in the MSH2 gene in LAPC4, PC3 and VCAP cell lines. MicroRNAs have also been implicated in the regulation of DNA repair genes, hence we performed an in silico screen to identify target microRNAs. MiR-21, mir-141 and miR-212 were identified as potential regulators of MSH2 and confirmed by western blot analysis. QPCR was performed to identify the patient expression profiles and hormonal regulation. Conclusion: This study has successfully identified a subpopulation of prostate cancers with low MSH2 expression and has illustrated that this phenotype is associated with recurrence. Additionally, androgen driven mechanisms have been identified as a potential cause of this loss, suggesting a unique link to prostate cancer compared to other cancer types. Objective: Understanding intra-tumour heterogeneity has fundamental implications for the treatment and prognostication of cancer. Many approaches have arisen for inferring the evolutionary dynamics and clonality landscapes of tumour cell populations from point-mutation and copy-number data. However, there are currently no methods that fully incorporate structural variation (SV). Copy-number neutral rearrangements are common in certain cancers such as prostate; however, there are currently no methods to investigate the clonality status of rearrangements. To address this gap, we present SVclone, the first integrated software package for investigating the clonality of tumour samples using SV calls from modest-coverage whole-genome sequencing data. Methods: We have developed a method which extracts and counts read information from whole-genome alignments, given a list of SV calls. We take these counts and infer variant allele frequencies (VAFs), which we input into a Bayesian model, which employs a cluster clustering process to dynamically infer the number of tumour populations and their relative proportions. We also incorporate copy-number states to correct allele frequencies in order to obtain a robust estimate of cancer cell fractions. Results: We tested our approach using simulations, and developed a series of corrections to account for VAF biases. To test the algorithm on real, noisy tumour data, we created in-silico mixtures of prostate cancer metastases samples in known proportions and could recapitulate the true proportions and cluster numbers with high accuracy, using a fraction of the data points that SNVbased methods use. We then applied our algorithm to over 2600 whole-genome sequencing samples as part of the Pancancer Analysis of Whole Genome project and uncovered novel patterns of subclonal SV enrichment across several tumour types. Conclusions: The evolution of tumours driven by large-scale (particularly balanced) rearrangements, such as prostate cancer, has not been fully explored. We have developed a tool to infer the clonality of whole-genome sequenced tumour samples, giving accurate results with a relatively small number of data points. Upon application to a large Pancancer dataset, we uncovered novel patterns of SV enrichment present in different tumour types. Objective: Ductal adenocarcinoma of the prostate is a rare non-acinar variant of prostatic carcinoma. In its pure form, it only accounts for 0.2-0.8% of all prostate cancers. This is in contrast to the majority of prostatic cancer cases where it is comprised purely of acinar adenocarcinoma. It has been described that individuals with ductal adenocarcinoma typically present at a more advanced clinicopathological stage and have an unfavourable prognosis when compared to their acinar adenocarcinoma counterparts. At present there is little literature regarding the genomic characteristics of ductal adenocarcinoma despite its aggressive clinical nature. Methods: A systematic literature search of Medline/Pubmed was conducted up to April 2017. The search criteria included any studies with the terms 'ductal adenocarcinoma', 'acinar adenocarcinoma', and 'prostate'. Results: A total of 124 studies dating from January 1984 to April 2017 were identified. Conclusions: At present there is little literature regarding the genomic characteristics of ductal adenocarcinoma despite its aggressive clinical nature. Studies have ranged from gene expression profiling to methods using Fluorescence in Situ Hybridization (FISH). For gene expression profiling, it concluded that ductal and acinar adenocarcinoma tumour types were too similar to distinguish on gene expression alone. FISH found that the common gene rearrangement TMPRSS2-ERG was less frequent in pure ductal adenocarcinoma. This highlights the existence of genetic and biological differences between ductal and acinar adenocarcinoma; however, this requires further exploration with possibly genome sequencing. Objective: The primary objective of this study was to quantify the autonomic nerve subtypes involved in perineural invasion (PNI) in prostate cancer. In addition, we evaluated the relationship between autonomic PNI subtypes and routine clinicopathological factors as well as biochemical recurrence. Methods: 98 men from our institutional prostate cancer biorepository, who were known to have PNI on radical prostatectomy specimen were studied. Relevant clinical data was extracted from a prospective database. Serial sections of formalin fixed paraffin embedded radical prostatectomy tissue were stained with S100 (pan-nerve marker) plus AEI/AE3, TH (sympathetic) and nNOS (parasympathetic). A hotspot method of analysis was used with 3 regions of intraprostatic PNI selected for each patient. PNI bundles identified were designated as pure sympathetic, pure parasympathetic, mixed bundle or double negative (somatic). Results: Median pre-operative PSA for the cohort was 8.8 and Gleason score 7. PSA recurrence occurred in 42%. Median follow-up was 85 months. 78% of all PNI bundles identified were mixed fibres. 16% were pure parasympathetic and 5% were pure sympathetic. Only 1% fibres were somatic. The total number of PNI bundles was associated with pT stage (p = 0.008), however this significance was lost when evaluating the relationship between specific PNI subtypes and pT stage. No significant relationship between PNI subtype and ISUP, Gleason score, PSA or biochemical recurrence was seen. Conclusions: There was no preferential involvement of autonomic nerve subtype of PNI in this cohort. PNI subtype was not predictive of biochemical recurrence. Further work is needed to clarify the biology of PNI.
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Periprostatic fat holds a field-effect transcriptional signature of cancer grade Objective: Current prostate cancer prognostic methods fail to discriminate indolent tumours from those with the potential to progress and metastasise. This uncertainty leads many patients to receive therapy that is improperly matched to their disease severity. An alternative involves investigating surrounding tissues to search for a "field-change" effect caused by cancers with different prognoses. Adipose tissue metabolism has been shown to be affected by a number of solid tumours, including prostate cancer so we investigated the transcriptome of periprostatic adipose tissue in two cohorts of high-and low-risk prostate cancer patients. Methods: Total RNA was extracted from periprostatic adipose tissue from a cohort of patients with either low-risk or highrisk prostate cancer and sequenced using an Illumina HiSeq 2500. After bioinformatics data processing, gene expression data was used to construct a 17-gene signature separating high-risk and low-risk disease which was then validated and refined by qRT-PCR. Results: 677 genes were found to be significantly differentially-regulated between our two cohorts. Interestingly, among the most differentially transcribed genes were a large number involved in inflammation and immune response. Although the overall differential range was low it was possible to generate a 17-gene signature that clearly separated high-risk from low-risk disease with an AUC of 1. After qRT-PCR validation of signature genes we were able to further refine the gene signature to differentiate between cohorts based on the expression of just three genes IGHA1, OLFM4 and RERGL. Conclusions: We performed a genome wide analysis of gene expression in periprostatic adipose tissue obtained from patients with low-and high-risk disease and identified a transcriptional signature that could distinguish between the two groups with high accuracy. We then translated and refined this signature this into a 3-gene qRT-PCR based assay which demonstrates discriminatory ability in an independent validation cohort, confirming the presence of a cancer related 'fieldeffect' in periprostatic adipose tissue that may be clinically exploitable.
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The role of FGF7 in castration resistant prostate cancer Objective: To investigate the development of castration resistant prostate cancer, and the role FGF7 has in enabling these cells to survive. Methods: A neo adjuvant trial consisting of a "super-castration" treatment with bicalutamide, abiraterone and degarelix treatment for a period of 6 months prior to radical prostactomy was conducted. DNA from 7 pre (formalin fixed paraffin bedded (FFPE)), 20 post (11 FFPE, 9 fresh frozen) and 14 germline (whole blood) samples were used for whole genome sequencing (WGS). Tissue was sequenced at 30X and blood at 15X depth on the Illumina HiTenX. RNA from 6 fresh frozen post treatment samples, and 8 matched hormone na€ ıve samples were used to construct a RNA-Seq library and sequenced at a length of 150 bp using paired end chemistry on an Illumina HiSeq. To validate the findings from the RNA-Sequencing data, LnCaP and LaPC4 cell lines were treated with FGF7, bFGF, TGFb, and LIF, and the cells proliferation and metabolism was measured using MTT assay. The effect of these proteins on the expression of other genes of interested was measured using qPCR. Results: Although we have found through WGS that there is an increase in single nucleotide variants (SNVs), and copy number variations (CNVs) in post samples as compared to germline and pre samples in some patients, this increase is not observed in other patients with a similar response to treatment. Preliminary RNA-Seq data has detected an epithelial to mesenchymal and a basal cell signature. It has also shown an increased expression in FGF7, and preliminary validation in cell lines treated with FGF7 indicates that it plays a role in the survival of cells when they are in a castrate environment, in addition to altering the expression of genes involved in the epithelial to mesenchymal transition, as well as other genes of interest which were found to have an altered expression in the super castration cohort. The cell composition and genetics of the tumour microenvironment have been shown to be key for the progression of a diverse range of cancers, as well as having prognostic predictive power (e.g., for colorectal cancer). However, the analysis of tissue cell composition and the genetics of single cell types usually requires flow cytometry technologies and tissue processing that ultimately affect the cell molecular content (e.g., RNA) and which are poorly scalable to large cohorts.
Here, I present ARMET (algorithm for resolving microenvironment transcriptomes) a robust, innovative computational tool for mapping whole cancer tissue transcriptional changes to single cell-types components (e.g., epithelial, fibroblasts and lymphocytes); in doing so the tissue composition is inferred for each tissue sample using the transcriptional data, with greater accuracy than any other publicly available tool. This tool is particularly suitable for large RNA-seq cohorts such as TCGA and PCAWG, and unlocks the high-throughput exploration of the cancer microenvironment at the molecular level, improving the resolution and interpretability of complex transcriptome data sets.
